Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.14 +2.21%

+$0.16 today

Market cap
$369.13M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.59M

Average 0.26M

Returns on capital

Puma Biotechnology, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

23.9%

avg 67.0%

ROIC

20.4%

avg -52.1%

ROA

14.4%

avg -41.9%

Analysis

ROE is currently the strongest return metric at 23.9% versus its period average of 67.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Alan H. Auerbach

Founder, Chairman, President, Chief Executive Officer & SecretaryUSD 1.98M567.26M14.27%

Maximo F. Nougues

Chief Financial Officer & Principal Accounting OfficerUSD 904.49K57230.64K0.45%

Douglas Hunt FRAPS

Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law OfficerUSD 797.76K61——

Kenneth Wiehe

Senior Vice President of Supply Chain & Manufacturing————

Roger L. Storms

Senior Vice President of Sales————

Heather Blaber

Senior Vice President of Marketing————

Pamela Wilson

Senior Vice President of Clinical Operations————

Gordon G. Esplin

Chief Accounting Officer—58——

Petra Rietschel

Senior Vice President of Clinical Development————

Mariann Ohanesian

Senior Director of Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

17

$2.14M

Net Transaction Value

−$2.14M

Net selling

Most Active

AUERBACH ALAN H

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 11, 26

MILLER MICHAEL PATRICK

Direct

Sell$121.5K
Sep 14, 26

WILSON TROY EDWARD

Direct

Sell$45.5K
Sep 14, 26

Cesano Alessandra

Direct

Sell$567K
Jul 6, 26

AUERBACH ALAN H

Direct

Sell$364.1K
Jul 6, 26

HUNT DOUGLAS M

Direct

Sell$69.9K
Jul 6, 26

NOUGUES MAXIMO F

Direct

Sell$77.6K
Jun 12, 26

MOYES JAY M

Direct

Sell$158.8K
Jun 12, 26

WILSON TROY EDWARD

Direct

Sell$77.7K
Jun 12, 26

Stuglik Brian M

Direct

Sell$58.3K
Jun 12, 26

Senderowicz Adrian

Direct

Sell$194.3K

1–10 of 17

Summary

Insiders reported 0 buys worth $0.00 and 17 sells worth $2.14M over the last 12 months. That adds up to net selling of $2.14M. AUERBACH ALAN H was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/A+210.9%
N/A1 analysts
RevenueN/AN/A+0.0%
+0.2% (5yr)1 analysts
Net IncomeN/AN/A+2396.3%
N/A1 analysts
EBITN/AN/A+16.3%
-24.3% (5yr)1 analysts

Analysis

Recent growth has been strongest in Net Income at +2396.3% over three years. Forward estimates point to Revenue at +0.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Puma Biotechnology, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PBYI's management, answered from reported figures.

Who manages PBYI?

Puma Biotechnology, Inc. (PBYI) lists 10 active executives. The top listed executive is Kenneth Wiehe, Senior Vice President of Supply Chain & Manufacturing.

Are PBYI insiders buying or selling?

Recent insider activity shows net buying of $12.24M.